Viking Therapeutics Files 8-K on Operations
Ticker: VKTX · Form: 8-K · Filed: Apr 24, 2024 · CIK: 1607678
Sentiment: neutral
Topics: operations, financials, sec-filing
Related Tickers: VKTX
TL;DR
Viking Therapeutics (VKTX) filed an 8-K updating investors on their financials and operations.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's business operations. Viking Therapeutics, Inc. is incorporated in Delaware and is part of the pharmaceutical preparations industry.
Why It Matters
This 8-K filing provides an update on Viking Therapeutics' financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine operational and financial update, not indicating any immediate or significant new risks.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- April 24, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
- 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121 (address) — Business Address
- 858-704-4660 (phone_number) — Business Phone
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Viking Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on April 24, 2024.
In which state is Viking Therapeutics, Inc. incorporated?
Viking Therapeutics, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification code for Viking Therapeutics, Inc.?
The Standard Industrial Classification code for Viking Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for Viking Therapeutics, Inc.?
The principal executive office address for Viking Therapeutics, Inc. is 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-04-24 16:05:11
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240424.htm (8-K) — 41KB
- vktx-ex99_1.htm (EX-99.1) — 175KB
- img201808844_0.jpg (GRAPHIC) — 13KB
- 0000950170-24-047567.txt ( ) — 369KB
- vktx-20240424.xsd (EX-101.SCH) — 30KB
- vktx-20240424_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On April 24, 2024, we issued a press release reporting our financial results for the first quarter ended March 31, 2024 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press release issued April 24, 2024, reporting financial results for the first quarter ended March 31, 2024 and providing a corporate update. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viking Therapeutics, Inc. Date: April 24, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)